AllianceBernstein’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.41M Buy
27,095
+2,800
+12% +$660K ﹤0.01% 1501
2026
Q1
$4.59M Buy
24,295
+124
+0.5% +$24.5K ﹤0.01% 1577
2025
Q4
$4.57M Buy
24,171
+1,918
+9% +$369K ﹤0.01% 1580
2025
Q3
$3.94M Buy
22,253
+1,576
+8% +$234K ﹤0.01% 1634
2025
Q2
$2.35M Hold
20,677
﹤0.01% 1853
2025
Q1
$2.17M Buy
20,677
+31
+0.2% +$3.51K ﹤0.01% 1847
2024
Q4
$2.21M Sell
20,646
-1,460
-7% -$165K ﹤0.01% 1908
2024
Q3
$2.21M Hold
22,106
﹤0.01% 1910
2024
Q2
$1.86M Sell
22,106
-913
-4% -$72.7K ﹤0.01% 1999
2024
Q1
$1.68M Buy
23,019
+1,460
+7% +$108K ﹤0.01% 2009
2023
Q4
$1.54M Sell
21,559
-20
-0.1% -$1.18K ﹤0.01% 2066
2023
Q3
$1.29M Hold
21,579
﹤0.01% 2108
2023
Q2
$1.56M Sell
21,579
-2,311
-10% -$173K ﹤0.01% 2039
2023
Q1
$1.76M Sell
23,890
-1,434
-6% -$102K ﹤0.01% 1939
2022
Q4
$1.69M Sell
25,324
-15,245
-38% -$991K ﹤0.01% 2018
2022
Q3
$2.18M Sell
40,569
-158
-0.4% -$9.29K ﹤0.01% 1834
2022
Q2
$2.27M Buy
40,727
+70
+0.2% +$3.97K ﹤0.01% 1881
2022
Q1
$2.85M Buy
40,657
+199
+0.5% +$14.4K ﹤0.01% 1880
2021
Q4
$3.9M Sell
40,458
-3,679
-8% -$340K ﹤0.01% 1755
2021
Q3
$3.84M Sell
44,137
-23,032
-34% -$1.78M ﹤0.01% 1753
2021
Q2
$5.5M Sell
67,169
-4,745
-7% -$395K ﹤0.01% 1558
2021
Q1
$6.84M Buy
71,914
+1,310
+2% +$124K ﹤0.01% 1389
2020
Q4
$4.38M Sell
70,604
-26,551
-27% -$1.51M ﹤0.01% 1563
2020
Q3
$5.78M Sell
97,155
-10,616
-10% -$724K ﹤0.01% 1273
2020
Q2
$7.52M Sell
107,771
-1,459
-1% -$92.5K ﹤0.01% 1123
2020
Q1
$4.96M Buy
109,230
+449
+0.4% +$25.4K ﹤0.01% 1189
2019
Q4
$7.08M Sell
108,781
-2,773
-2% -$185K ﹤0.01% 1234
2019
Q3
$6.93M Sell
111,554
-1,924
-2% -$121K ﹤0.01% 1205
2019
Q2
$8.08M Sell
113,478
-4,889
-4% -$360K 0.01% 1145
2019
Q1
$9.28M Buy
118,367
+4,536
+4% +$344K 0.01% 1090
2018
Q4
$9.64M Buy
113,831
+39,437
+53% +$4.2M 0.01% 1008
2018
Q3
$12.7M Sell
74,394
-481
-0.6% -$72.5K 0.01% 911
2018
Q2
$9.68M Buy
74,875
+1,555
+2% +$174K 0.01% 980
2018
Q1
$7.55M Sell
73,320
-513
-0.7% -$50.7K 0.01% 1027
2017
Q4
$6.31M Hold
73,833
﹤0.01% 1113
2017
Q3
$6.27M Hold
73,833
﹤0.01% 1112
2017
Q2
$5.59M Buy
73,833
+12,279
+20% +$859K ﹤0.01% 1157
2017
Q1
$4.06M Buy
61,554
+9,602
+18% +$632K ﹤0.01% 1318
2016
Q4
$3.29M Hold
51,952
﹤0.01% 1471
2016
Q3
$3.31M Hold
51,952
﹤0.01% 1394
2016
Q2
$3.87M Buy
51,952
+7,374
+17% +$547K ﹤0.01% 1197
2016
Q1
$2.98M Sell
44,578
-5,129
-10% -$312K ﹤0.01% 1328
2015
Q4
$3.36M Sell
49,707
-6,012
-11% -$371K ﹤0.01% 1249
2015
Q3
$2.98M Sell
55,719
-6,460
-10% -$392K ﹤0.01% 1348
2015
Q2
$3.91M Sell
62,179
-1,603
-3% -$87.5K ﹤0.01% 1250
2015
Q1
$3.07M Hold
63,782
﹤0.01% 1426
2014
Q4
$2.12M Hold
63,782
﹤0.01% 1718
2014
Q3
$1.87M Hold
63,782
﹤0.01% 1774
2014
Q2
$2.48M Sell
63,782
-168
-0.3% -$6.82K ﹤0.01% 1614
2014
Q1
$2.68M Buy
63,950
+9,607
+18% +$400K ﹤0.01% 1493
2013
Q4
$1.78M Sell
54,343
-3,036
-5% -$98.9K ﹤0.01% 1802
2013
Q3
$1.55M Sell
57,379
-3,719
-6% -$105K ﹤0.01% 1866
2013
Q2
$1.43M Buy
+61,098
New +$1.1M ﹤0.01% 1854

Other funds holding LGND

AllianceBernstein's LGND Position: Q2 2026 in Review

AllianceBernstein increased its Ligand Pharmaceuticals (LGND) stake by 12% in Q2 2026, buying an estimated $660K and bringing the position to 27,095 shares worth $5.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1501.

AllianceBernstein first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.7M in Q3 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • AllianceBernstein held 27,095 shares of Ligand Pharmaceuticals worth $5.41M as of Q2 2026.
  • AllianceBernstein bought 2,800 Ligand Pharmaceuticals shares in Q2 2026, an estimated $660K.
  • Ligand Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1501 holding.
  • AllianceBernstein first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • AllianceBernstein's Ligand Pharmaceuticals position peaked at $12.7M in Q3 2018.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.